Precision BioSciences (DTIL) Stock Price, News & Analysis

Company Overview

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $4.94 to $5.22
• 50-Day Range: $4.23 to $5.75
• 52-Week Range: $3.61 to $13.25
• Volume: 57,592 shs
• Average Volume: 183,746 shs
• Market Capitalization: $56.55 million
• P/E Ratio: 85.01
• Dividend Yield: N/A
• Price Target: $47.00
• Consensus Rating: Buy

Precision BioSciences Stock Analysis - MarketRank™

Precision BioSciences scored higher than 80% of companies evaluated by MarketBeat, and ranked 191st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Precision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Precision BioSciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precision BioSciences is 85.01, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precision BioSciences is 85.01, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.08.

Price to Book Value per Share Ratio

Precision BioSciences has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.76% of the float of Precision BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Precision BioSciences has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Precision BioSciences has recently decreased by 3.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precision BioSciences does not currently pay a dividend.

Dividend Growth

Precision BioSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.99

Percentage of Shares Shorted

21.76% of the float of Precision BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Precision BioSciences has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Precision BioSciences has recently decreased by 3.06%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Precision BioSciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Precision BioSciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Precision BioSciences insiders have bought 221.36% more of their company's stock than they have sold. Specifically, they have bought $17,225.00 in company stock and sold $5,360.00 in company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Precision BioSciences is held by insiders.

Percentage Held by Institutions

Only 37.99% of the stock of Precision BioSciences is held by institutions.

DTIL Stock Analysis - Frequently Asked Questions

How have DTIL shares performed this year?

Precision BioSciences' stock was trading at $3.81 at the beginning of 2025. Since then, DTIL shares have increased by 33.9% and is now trading at $5.10.
View the best growth stocks for 2025 here.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its earnings results on Thursday, May, 15th. The company reported ($2.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $1.78. The company earned $0.03 million during the quarter, compared to analysts' expectations of $5 million. Precision BioSciences had a negative trailing twelve-month return on equity of 23.69% and a net margin of 11.48%.

When did Precision BioSciences' stock split?

Shares of Precision BioSciences reverse split on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

Who are Precision BioSciences' major shareholders?

Precision BioSciences' top institutional investors include Tejara Capital Ltd (0.57%), Moloney Securities Asset Management LLC (0.41%) and Miller Financial Services LLC (0.09%). Insiders that own company stock include Derek Jantz, J Jefferson Smith, John Alexander Kelly, Geno J Germano, Melinda Brown, Dario Scimeca and Alan List.
View institutional ownership trends.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia Oyj (NOK) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/05/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DTIL
• CIK: 1357874
• Web: www.precisionbiosciences.com
• Phone: (919) 314-5512
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $34.00
• Potential Upside/Downside: +821.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.01)
• Trailing P/E Ratio: 85.01
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.32 million
• Net Margins: 11.48%
• Pretax Margin: 15.28%
• Return on Equity: -23.69%
• Return on Assets: -6.98%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 9.22
• Quick Ratio: 9.22

Sales & Book Value

• Annual Sales: $51.14 million
• Price / Sales: 1.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.53 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 11,088,000
• Free Float: 7,364,000
• Market Cap: $56.55 million
• Optionable: No Data
• Beta: 1.55